Table 1.
Demographic and baseline characteristics of the study participants
| mRNA-1944 | mRNA-1944 | mRNA-1944 | mRNA-1944 | mRNA-1944 | mRNA-1944 | Placebo | Overall | |
|---|---|---|---|---|---|---|---|---|
| 0.1 mg kg−1a | 0.3 mg kg−1a | 0.6 mg kg−1b | 0.6 mg kg−1 + steroidc | 0.3 mg kg−1 2-dosed,e | All | All | ||
| n = 6 | n = 6 | n = 4 | n = 6 | n = 6 | n = 28 | n = 10 | n = 38 | |
| Age, years mean (range) | 34.0 (20–43) | 37.5 (32–50) | 36.3 (23–49) | 36.2 (24–49) | 34.7 (20–46) | 35.7 (20–50) | 33.2 (24–46) | 35.0 (20–50) |
| Women, n (%) | 3 (50.0) | 4 (66.7) | 1 (25.0) | 5 (83.3) | 2 (33.3) | 15 (53.6) | 5 (50.0) | 20 (52.6) |
| Race, n (%) | ||||||||
| White | 4 (66.7) | 5 (83.3) | 2 (50.0) | 6 (100) | 3 (50.0) | 20 (71.4) | 8 (80.0) | 28 (73.7) |
| Black or African American | 2 (33.3) | 1 (16.7) | 1 (25.0) | 0 | 3 (50.0) | 7 (25.0) | 1 (10.0) | 8 (21.1) |
| Other | 0 | 0 | 1 (25.0) | 0 | 0 | 1 (3.6) | 1 (10.0) | 2 (5.3) |
| Weight, mean kg | 85. 8 | 78.8 | 85.3 | 69.6 | 68.2 | 77.0 | 73.2 | 76.0 |
| BMI, mean kg m−2 | 29.9 | 29.6 | 30.3 | 24.8 | 25.6 | 27.9 | 25.0 | 27.1 |
Percentages are based on the number of participants in the safety population who received the specified treatment and the total number in each group. aParticipants received loratadine and ranitidine 90 min before infusion. bParticipants received loratadine, ranitidine (sentinel, expansion) and acetaminophen (expansion) 90 min before infusion. cParticipants received steroid (dexamethasone) and diphenhydramine and famotidine 90 min before infusion. dParticipants received diphenhydramine and famotidine 90 min before infusion. eParticipants were administered two 0.3 mg kg−1 doses on days 1 and 8.